Fruzaqla
What Fruzaqla is used for
Fruzaqla as monotherapy is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan based chemotherapies, anti VEGF agents, and anti EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine tipiracil or regorafenib.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Fruzaqla
- Active substance
- fruquintinib
- Disease area
- Colorectal Neoplasms
- Medicine group
- Antineoplastic agents
- ATC code
- L01EK
- Marketing authorisation holder
- Takeda Pharmaceuticals International AG Ireland
- Authorised in the EU since
- 2024
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Fruzaqla used for?
Fruzaqla as monotherapy is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan based chemotherapies, anti VEGF agents, and anti EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine tipiracil or regorafenib.
What is the active substance in Fruzaqla?
Fruzaqla contains fruquintinib.
Who makes Fruzaqla?
The EU marketing authorisation holder is Takeda Pharmaceuticals International AG Ireland.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU